Stock Thesis
LDOS: Stock thesis & analysis
As of 2026-08-15
📁 From our research archive: this thesis was generated on 2026-08-15 and may not reflect our current view. See the latest research →
LDOS screens as an ORPHAN: reasonable valuation (P/E 13.4x, P/FCF 15.8x) and solid ROE of 27.8%, but only 1 fund holds the stock with a single quarter of persistence — well short of any confirming smart-money tier. Elevated leverage (D/E 123%) and a modest 11.7% operating margin temper the quality picture despite the technology sector's leadership positioning this cycle. Without institutional conviction or a specific catalyst addressing why funds are largely absent from a well-known government-services franchise, this defaults to PASS per the orphan rule.
Catalysts to watch
- Potential contract wins or renewals disclosed in upcoming 10-Q
- Analyst coverage initiation cycle (6 initiations in 30 days) could resolve into upgrades if fundamentals hold
- Sector rotation into Technology (currently ranked 2 of 11) could lift multiple if smart-money interest follows
Key risks
- Low institutional conviction (only 1 fund holding) despite reasonable fundamentals
- High leverage relative to sector peers (D/E 123%)
- Government-services revenue concentration exposes name to federal budget/contract risk
- Two insider sales in the last 30 days with no offsetting purchases
- Late-cycle credit conditions (HY OAS complacency) warrant caution on leveraged balance sheets
What would change the view
- Stock breaks below $128.00 (below recent support and near 52-week range floor)
- Operating margin falls below 10% for two consecutive quarters
- D/E ratio rises above 150% without a corresponding EBITDA growth catalyst
More AI stock thesis reports
Already subscribed? Unlock this device →
Not financial advice. This is the published output of an AI-driven, human-in-the-loop research process on a paper (simulated) account: informational only, not personalized investment advice, and not a solicitation to buy or sell any security. Past performance does not guarantee future results. Do your own research and trade at your own discretion in your own account. See the full disclaimer, terms & privacy.